Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief...

Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and
Chief Medical Officer

--Dr. Sherman also elected President of the Drug Information Association
(DIA)--

NORTHBROOK, Ill., June 29 /PRNewswire/ -- Horizon Therapeutics, Inc., a
privately held biopharmaceutical company, today announced the appointment of
Jeffrey W. Sherman, M.D., F.A.C.P., as its executive vice president and chief
medical officer.

Dr. Sherman brings more than 20 years of pharmaceutical experience to Horizon
and will lead the regulatory and clinical strategy for Horizon's
investigational therapies for mild-to-moderate arthritis and pain, including
HZT-501, a fixed-dose combination tablet containing the most prescribed
non-steroidal anti-inflammatory drug (NSAID), ibuprofen, with a high dose of
the most potent H2 antagonist, famotidine. HZT-501 was shown to significantly
reduce the incidence of NSAID-induced upper gastrointestinal ulcers in
patients with mild-to-moderate pain in two Phase 3 studies.

Dr. Sherman joins Horizon from IDM Pharma, which was recently purchased by
Takeda Pharmaceuticals Limited, where he led the clinical, regulatory, and
development teams that secured European Commission approval for MEPACT(R)
(mifamurtide, L-MTP-PE), a treatment for non-metastatic, resectable
osteosarcoma. Prior to IDM Pharma, Dr. Sherman served as vice president of
clinical science at Takeda Global Research & Development Center, Inc., a
subsidiary of Takeda Pharmaceutical Company Limited, where he was focused on
developing Takeda's oncology pipeline. Dr. Sherman also held the position of
chief medical officer and executive vice president at NeoPharm, Inc., and held
numerous research development and marketing roles at Searle/Pharmacia,
including responsibility for the COX-2 (Celebrex) oncology program.

"Dr. Sherman has significant experience in the biotechnology and
pharmaceutical industry, with a proven track record of success in bringing
drugs through the regulatory process," said Timothy P. Walbert, president and
chief executive officer of Horizon Therapeutics. "Dr. Sherman will oversee
the preparation and submission of the HZT-501 regulatory applications to U.S.
and European regulatory authorities, while helping us manage the clinical
development of our other pain therapies."

In addition to his Horizon appointment, Dr. Sherman was recently elected
President of the Drug Information Association (DIA), a global, nonprofit,
multidisciplinary, professional association of approximately 18,000 members
which provides a neutral forum for sharing information that optimizes the
process of drug development and lifecycle management. He has been a member of
the DIA Board of Directors for nearly seven years and in 2001, received the
association's "Outstanding Service Award."

About Horizon Therapeutics
Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused
on the development and commercialization of therapies for the treatment of
mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes
innovative combination therapies in early- and late-stage development that are
designed to improve safety, efficacy and patient compliance. For more
information about the company and its products, please visit
www.horizontherapeutics.com.

SOURCE Horizon Therapeutics, Inc.

Robert De Vaere, Executive Vice President, Chief Financial Officer of Horizon
Therapeutics, Inc., +1-760-436-4010, bdevaere@horizontherapeutics.com, or
Carolyn Wang of WeissComm Partners, +1-415-946-1065, cwang@wcpglobal.com, for
Horizon Therapeutics, Inc.